Post on 28-Dec-2015
Supplemental Figure 1
Tissue:
Colorectum Lungs Vaginal wall
Route: ICR IN IVAG IVAG (Depo)Dose: 2x109 5x108 1x109
0123456789
Lu
c R
LU
(lo
g1
0)RLU/mg tw RLU/tissue
******
**
Supplemental Figure 2
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50
Mo
rtal
ity
0.0
1.0
2.0
3.0
4.0
5.0
1 2 3 4 5 6 7 8 9P
ath
olo
gy
Sco
re 2×106 PFU
2×105 PFU
2×104 PFU
2×103 PFU
2×102 PFU0.01.02.03.04.05.06.0
1 2 3 4 5 6 7
To
tal P
FU
/sam
ple
Days post infection
Mortality Rectal virus shedding Perianal pathology
Supplemental Figure 3
Unprotected Protected after AdgB ICR
Supplemental Figure 4
Pa
tho
log
y s
co
re
0
1
2
3
4
5
0 1 2 3 4 5 6 70
20
40
60
80
100
Mo
rta
lity
(%
)
0 10 20 30 40 50
CD8-/-
IFN--/-
IL-12-/-
Days post infection
Perianal pathology Mortality
WT
Supplemental Figure 5
a
b
0.0
1.0
2.0
3.0
4.0
5.0
7
To
tal P
FU
/sam
ple ***
**
***
0
1
2
3
4
5
1 2 3 4 5 6 7
Pat
ho
log
y sc
ore ***
***
***
***
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50
Mo
rtal
ity
Unimmunized AdgB IN/IN AdgB ICR/IN
0
1
2
3
4
5
1 2 3 4 5 6 7
Pat
ho
log
y sc
ore
***
***
*
0.0
1.0
2.0
3.0
4.0
5.0
7
To
tal P
FU
/sam
ple***
***
***
***
0%
20%
40%
60%
80%
100%
0 10 20 30 40 50M
ort
alit
y
Days post infection
Days post infection
Perianal pathology Rectal virus shedding Mortality
Perineal pathology Vaginal virus shedding Mortality
Supplemental Figure 6
a
b
0
20
40
60
80
100
0 10 20 30 40 50
Mo
rta
lity
(%
)
Unimmunized
AdgB IVAG (Depo)
AdgB IVAG
Pa
tho
log
y s
co
re
0
1
2
3
4
5
0 1 2 3 4 5 6 7
Pa
tho
log
y s
co
re
0
1
2
3
4
5
0 1 2 3 4 5 6 70
20
40
60
80
100
Mo
rta
lity
(%
)
0 10 20 30 40 50
Unimmunized
AdgB IVAG (Depo)
AdgB IVAG
Days post infection
Days post infection
Perianal pathology Mortality
Perianal pathology Mortality
Supplemental Figure 1 Local gene transfer by different mucosal routes. At two
days after AdLuc administration via ICR, IN and IVAG (with or without prior Depo-
Provera treatment), luciferase activities were determined by measuring
luminescence in each corresponding tissue as RLU per tw (density) or whole
organ tissue (total mass). At specified doses used for immune function studies,
there was no statistical difference in the density or total mass of gene expression
among different locations (P > 0.05) except for the vaginal tissue after IVAG
without Depo-Provera and the mass after IVAG with Depo-Provera. Averaged
density of gene expression in the colorectum did not exceed that in the lung or
vaginal tract. The values are the mean ±s.d. of 3 mice in each group. Asterisks
indicate significantly lower RLU compared to other groups.
Supplemental Figure 2 Perianal inflammation (pathology) and hindlimb paralysis
developed in the HSV-2 rectal challenge model. Doses of HSV-2 for rectal
challenge were titrated (N=10/group except for the groups of 2x102 and 2x103,
N=5). The absolute lethal dose (LD100) of HSV-2 was determined as 1x105 PFU,
at and above which animals developed 100% hindlimb paralysis (left panel; 100%
mortality) and the disease never resolved. Similar to vaginal HSV-2 infection
(76;80), rectally infected mice having received LD doses displayed uncontrolled
virus replication (middle panel; relatively constant from day 1 till death, with a
tendency to increase at day 2-3), increasingly severe perianal inflammation and
ulcerative lesions (right panel), and paralysis of hindlimbs developed within 7-10
days.
Supplemental Figure 3 Protection from HSV-2 rectal challenge in mice
immunized ICR with AdgB. Left panel: at day 7 after rectal challenge of 2x105
PFU of HSV-2, unimmunized mice developed the disease, severe perianal lesion
(white arrow) and paralyzed hindlimb (black arrow). Right panel: in contrast, AdgB
ICR immunized mice survived with diminished pathology and the disease was
completely resolved by day 7 (no lesion or paralysis developed).
Supplemental Figure 4 Protection at the large intestinal mucosa against HSV-2
depends on cellular immunity. Fourteen days after AdgB ICR immunization of
gene knockout mice as indicated, mice were challenged rectally with 2x105 PFU
of HSV-2. Pathology score (left panel) and mortality (right panel) were measured.
At least 5 mice in each group.
Supplemental Figure 5 Mucosal prime/boost vaccination requires large intestine
immunization to induce full protection against herpes infection. Intranasal
prime/boost (IN/IN) is often used to enhance mucosal immune responses. This
regimen was compared with priming/boosting of mice by ICR/IN with a 2-week
interval. Two weeks after the boost, animals were challenged with HSV-2 at a
dose of 2x106 PFU at colorectal mucosa (a) or 2x105 PFU at vaginal mucosa (b)
(N=5/group). Parianal pathology (left panels), virus shedding (middle panels) and
mortality (right panels) were compared. Asterisks in left panels and right panels
indicate a statistical difference of the group in comparison with ICR/IN group.
Although IN/IN was statistically different from unimmunized in pathology (left
panel, p<0.05) and mortality (right panel, p<0.01), ICR/IN provided more potent
mucosal protection than IN/IN. *, ** and *** indicate p<0.05, 0.01 and 0.001,
respectively.
Supplemental Figure 6 IVAG immunization fails to protect from HSV-2
challenge. Mice were immunized IVAG with 1x109 PFU of AdgB with or without
prior Depo-Provera (33) and 3 weeks later challenged with 2x105 PFU of HSV-2
at either vaginal (a) or colorectal mucosa (b). Pathology (left panels) and mortality
(right panels) were examined. N=5/group. No protection was seen after IVAG
immunization.